Vinyl Ether/Tetrazine Pair for the Traceless Release of Alcohols in Cells

Ester Jiménez-Moreno, Zijian Guo, Bruno L. Oliveira, Inês S. Albuquerque, Annabel Kitowski, Ana Guerreiro, Omar Boutureira, Tiago Rodrigues, Gonzalo Jiménez-Osés, and Gonçalo J. L. Bernardes*  

Abstract: The cleavage of a protecting group from a protein or drug under bioorthogonal conditions enables accurate spatiotemporal control over protein or drug activity. Disclosed herein is that vinyl ethers serve as protecting groups for alcohol-containing molecules and as reagents for bioorthogonal bond-cleavage reactions. A vinyl ether moiety was installed in a range of molecules, including amino acids, a monosaccharide, a fluorophore, and an analogue of the cytotoxic drug duocarmycin. Tetrazine-mediated decaging proceeded under biocompatible conditions with good yields and reasonable kinetics. Importantly, the nontoxic, vinyl ether duocarmycin double prodrug was successfully decaged in live cells to reinstate cytotoxicity. This bioorthogonal reaction presents broad applicability and may be suitable for in vivo applications.

Bioorthogonal chemistry for covalently conjugating synthetic molecules at a predefined protein residue has been a major focus of research in the past two decades.[1] Very recently, focus has been placed on reactions which can instead cleave specific bonds under bioorthogonal conditions.[2] This strategy holds great potential for the precise spatiotemporal control of protein function in vivo.[3,4] For example, photo-deprotection of a genetically encoded caged cysteine could be used to reveal the active native protein in live cells.[5] Similarly, palladium-mediated depropargylation,[6] phosphine-mediated Staudinger reduction,[7] and tetrazine-triggered inverse electron-demand Diels–Alder (IEDDA) elimination reactions[8] were successfully employed to restore the activity of proteins bearing a caged lysine residue in the active site. Bond-cleavage reactions are also attractive for drug-delivery applications. Palladium-catalyzed deperturbation of a 5-fluorouracil prodrug was shown as a method for controlled drug release in vivo.[9] The IEDDA reaction between a tetrazine and a caged doxorubicin derivative efficiently releases the cytotoxic drug.[8] Strategies based on IEDDA elimination reactions with tetrazines are particularly attractive for decaging relevant molecules in cells and interrogating biology, because of the favorable kinetics and the abiotic nature of tetrazines when compared to photo- and metal-catalyzed reactions. One limitation, however, has been the breadth of protecting groups available for stable, yet conditionally reversible linkages. Typically, IEDDA elimination reactions have been used with strained alkene protecting groups connected through a carbamate, thus resulting in a cascade release of a primary amine (Figure 1a).[2,9] Furthermore, the reduced metabolic stability of strained alkenes constitutes a major caveat for its utility. For instance, cis-cyclooctene easily isomerizes to the non-reactive trans-cyclooctene, thus limiting the efficiency of the decaging process in cells.[10]

Herein, we report the development of a vinyl ether/tetrazine system as IEDDA reaction partners for the traceless
decaging of alcohol-containing molecules. We demonstrate the broad applicability of this reaction on several chemotypes, including the protected amino acids serine and tyrosine, an 1,6-anhydro sugar, a fluorophore, and a drug. Importantly, the reaction proceeds under physiological conditions (aqueous buffer pH 7.4 and 37 °C) and was applied to activate a potent toxic derivative of the drug duocarmycin in cancer cells.

To harness the current chemical biology toolbox and develop a broadly applicable technology for the controlled release of alcohol-containing chemotypes, we set out to develop bioorthogonal bond-cleavage reactions. In particular, we envisaged that vinyl ethers could efficiently mask both aliphatic and aromatic hydroxy groups, and be used for traceless release of alcohols through a tetrAzine IEDDA bond-cleavage reaction. In fact, the reactivity of the vinyl group with tetrAzines has been detailed in organic synthesis[11] and such a reactive pair was very recently employed to visualize and detect RNA under bioorthogonal conditions.[12]

We first used commercial phenyl vinyl ether 1a as a model compound, and tetrAzine 2a to challenge our decaging hypothesis (Figure 1b–d). After reaction with 2a, phenol (3a) and 3,6-di(pyridin-2-yl)pyridazine (4a) were obtained in 49% and 61% yield, respectively (Table 1). The reaction was performed in dichloromethane to ensure that all the reagents were soluble and at room temperature with only two molar equivalents of tetrAzine. Increasing the amount of tetrAzine showed no significant improvement in reaction yield. To assess the scope of the reaction we then synthesized vinyl ether derivatives 1b–e.[13] Tyrosine and serine residues play a paramount role in the building of binding pocket architecture and controlling catalytic cycles, for example, in tyrosine kinases and serine proteases. Indeed, bioorthogonal decaging of catalytically crucial residues is emerging as a disruptive technology in chemical biology.[2] Furthermore, chromone-based fluorophores and sugars can efficiently be used to interrogate biological systems.[10] Remarkably, decaging vinyl ether derivatives of such molecules 1b–e with 2a gave the corresponding free hydroxy derivatives in good yields (50–68% yields after purification by column chromatography; Table 1). Of note, the vinyl ether reagents were generally stable under biocompatible conditions (PBS pH 7.4 at 37 °C) over 8 hours, as assessed by HPLC/UV (Table 1; see the Supporting Information). While some degree of instability was observed for 1c, for instance, the free hydroxy-containing molecule was not detected.

After confirming the stability of the vinyl ether molecules in pH 7.4 buffer and their successful tetrAzine-mediated decaging, we proceeded to study the reaction mechanism in detail through quantum mechanics at the M06-2X/6-31 + G(d,p) level of theory (Figure 2a; see the Supporting Information). Unlike tetrAzine reactions with highly reactive strained alkenes,[9] our data indicate that the first step, that is, the IEDDA cycloaddition, is the rate-limiting step of the reaction (TS1, ΔG* ≈ 25 kcal mol−1; reaction time ca. 3 days) followed by very fast retro-Diels–Alder (TS2anti, ΔG* ≈ 7 kcal mol−1) and phenoxy group cleavage (TS3, ΔG* ≈ 11 kcal mol−1). Once the 4-phenoxy-4,5-dihydropyridazine (int2) is obtained, it readily tautomerizes into 4-phenoxy-1,4-dihydropyridazine (int4), which can swiftly decage through an elimination reaction. Of note, other dihydropyridazine tautomers previously reported to undergo decaging (int3),[6,8] are unreactive in this reaction. To support the theoretical data, we mixed 1a

Table 1: Stability of vinyl ethers 1a–e and their decaging with tetrAzine 2a.

| Vinyl ethers[a] | Alcohol | Pyrazidine | Conv.[%] | Stability[b] |
|----------------|---------|------------|---------|-------------|
| 1a[b]          | 61      | 49         | 100     | 100         |
| 1b             | 68      | 65         | 73      | 100         |
| 1c             | 57      | 72         | 100     | 77          |
| 1d             | 50      | 47         | 56      | 77          |
| 1e             | 65      | 50         | 100     | n.d.        |

[a] The reactions were performed in dichloromethane at room temperature with 1 equiv of vinyl ether (100 mM) 1a–e and 2 equiv of tetrAzine 2a (200 mM) for 72 hours. [b] The reaction was complete after 40 hours. [c] Yield of isolated product. [d] The stability (as % of remaining starting compound) was assessed by HPLC in PBS pH 7.4 at 37 °C with a concentration of vinyl ether of 200 μM using acetonaphone as an internal standard. [e] 10% H2O in DMF. [f] 1e does not absorb in the UV. n.d. = not determined.

Figure 2. a) Proposed mechanism based on quantum mechanics for the IEDDA cycloaddition of 1a and 2a, followed by in situ alcohol release. Only the relevant activation free energies (ΔG*) are shown. The initial cycloaddition is the rate-limiting step. After very fast nitrogen cleavage, different dihydropyridazine tautomers int2–int4 equilibrate before irreversibly decaging to the experimentally obtained products (3a and 4a). See Figure S4 in the Supporting Information for the whole calculated minimum energy pathway. b) 1H NMR release studies of 1a upon reaction with 2a. The reaction was performed at 3 mM of 1a and 2a in 10% D2O/CD3CN. The reaction was monitored for 96 h. While the reaction was not always complete at 96 h, the results obtained were consistent with the mechanism supported by the theoretical calculations. Ph = phenyl, Py = pyridine.
Table 2: Kinetics of the reaction of 1a with the tetrazines 2a–c.

|   | Dienophile | 1a | 2b | 2c | 2a  |
|---|------------|----|----|----|-----|
| 2a | 1a         | 3.92±0.11 |
| 2b | 1a         | 0.063±0.013 |
| 2c | 1a         | 5.37±0.13 |
| 2a | 5-norbornen-2-ol | 1890±40 |

[a] The reactions were performed in 10% H₂O in DMF and were followed by UV through the decay of UV absorption of the tetrazines. An excess of tetrazine absorbance, that is, the rate-limiting step, in the visible region. We used 1a and screened tetrazines 2a–c, which included different substituents (Figure 1 and Table 2).

Supporting Information for A549 cells. In short, after incubation with 25 μM of 1d for 5 hours, 2c (10 μM) was added to the cells for 4 hours. At this time, cells were imaged using confocal microscopy and the turn-on fluorescence of the released coumarin was recorded as a result of the successful tetrazine decaging of the vinyl ether protecting group installed in 1d (Figure 3c). Importantly, this study highlights the biocompatibility of this approach for turn-on live cell imaging applications.

Stability studies of 1a in the system solvent used (10% H₂O in DMF) showed no significant degradation after 8 hours. As expected, tetrazines bearing electron-withdrawing groups (2a) led to faster reactions compared to the one bearing electron-donating ones (2b). Finally, 2c proved to have the fastest kinetics, probably because of the reduced steric hindrance brought about by hydrogen-substituted tetrazines. We also compared the kinetics of the vinyl ether/tetrazine decaging with a very reactive, strained alkene as reference, 5-norbornen-2-ol. The second-order rate constant determined (k₂ = 0.189 M⁻¹ s⁻¹) in 10% H₂O in DMF, although lower, compares well with literature values for the same reaction (k₂ = 1.3 M⁻¹ s⁻¹ in H₂O at 20°C). The differences observed are attributed to the faster IEDDA reactions in polar protic solvents.

To show the potential bioorthogonality of this bond-cleavage reaction, we next studied its use for the decaging of a vinyl ether fluorogenic probe in live cells (Figure 3a). To this end, we used a vinyl ether nonfluorescent coumarin derivative (1d) and 2c, as both were shown to be nontoxic to HepG2 cells at the concentrations used (Figure 3b; see the Supporting Information for A549 cells). In short, after incubation with 25 μM of 1d for 5 hours, 2c (10 μM) was added to the cells for 4 hours. At this time, cells were imaged using confocal microscopy and the turn-on fluorescence of the released coumarin was recorded as a result of the successful tetrazine decaging of the vinyl ether protecting group installed in 1d (Figure 3c). Importantly, this study highlights the biocompatibility of this approach for turn-on live cell imaging applications.

The targeted delivery of drugs to diseased tissues remains a topic of intensive study, and an unsolved issue in modern drug discovery. Currently, alcohol-containing drugs account for approximately 50% of all small FDA-approved chemical entities (cf. DrugBank v5.0; see the Supporting Information), thus providing ample opportunity for the design of innovative drug delivery constructs. As a proof-of-concept for our technology we assessed the spatiotemporal delivery of a duocarmycin-like natural product (5; Figure 4a). Duocarmycins are isolated from Streptomyces spp. bacterial[17] and have attracted considerable attention as payloads in antibody–drug conjugates, given their potent cytotoxic activity.[18] Interestingly, halogen-bearing duocarmycin cytotoxins undergo a Winsten spiropyranization reaction to afford the bioactive cyclopropanyl, a DNA-alkylating species. This feature has been explored in antibody-directed enzyme prodrug therapy, where a nontoxic glycosidic derivative of duocarmycin is activated by a conjugate of an enzyme and a tumor-specific antibody.[19] To demonstrate that our tetrazine-mediated IEDDA cleavage of vinyl ethers could be applied for the traceless release of an alcohol-containing drug, we synthesized the N-Ac-double prodrug 5 in three steps from...
the N-Boc-protected 1,2,9a-tetrahydrocyclopenta[1,2-c]-benz[1,2-c]-indol-4-one (CBI) starting material (see the Supporting Information for details). 20 We chose this simple duocarmycin analogue featuring only an acetyl group attached to the DNA-alkylating CBI core because it has been shown to be very toxic to rapidly replicating cells. 21 We envisioned that upon tetrazine IEDDA deprotection of the vinyl ether, the halogen prodrug 6 would be readily formed and undergo a rapid Winston spirocyclization reaction to afford active drug 7. This tetrazine-triggered cascade formation of an active drug through an intermediate prodrug is known as the double prodrug concept. 22

Next we studied the stability of the double prodrug 5 in PBS pH 7.4 at 37°C using HPLC. While species 6 and active drug 7 were not formed, we detected some degree of degradation of 5 over time (of note, formation of neither 6 or 7 was observed). Importantly, 5 was found to be less toxic when compared with the active drug 7 in both HepG2 and A549 cells (Figure 4d,e; see the Supporting Information). Having a suitable masked vinyl ether double prodrug in hand, we performed a decaging reaction under physiological conditions (PBS pH 7.4 at 37°C) with 2c. Remarkably, close to complete formation of 7 was achieved after 7 hours at 37°C in PBS pH 7.4, with the short-lived species 6 as an intermediate (Figure 4c). After successful demonstration of decaging of 5 under physiologically relevant conditions, we next proceeded to evaluate the feasibility of this approach for the tetrazine-mediated drug-delivery. A549 cells were first incubated with 5 for 24 hours, after which time 2c was added for an additional 46.5 hour period (twice the doubling time of these cells and comparable to our cytotoxicity studies; Figure 4b,c). Satisfyingly, we observed that at 10 μM, the product formed upon tetrazine-decaging of 5 is as toxic as 7 alone (Figure 4f; see the Supporting Information for identical study on HepG2 cells), thus suggesting complete drug activation in cells. Hence, this data advocates that tetrazine-mediated bond cleavage of vinyl ethers may be used for the traceless release of alcohol-containing drugs.

In summary, we described a vinyl ether/tetrazine pair as IEDDA reaction partners for the efficient traceless decaging of alcohol-containing molecules in live cells. Considering the wealth of hydroxy groups in chemical probes and drugs, coupled to the need of circumventing adverse drug reactions, the spatiotemporal delivery method disclosed herein may find broad applicability in chemical biology and molecular medicine by unraveling new biology and leveraging the controlled modulation of (patho)physiological events. Additionally, and in combination with strategies for the genetic encoding of vinyl-ether-protected tyrosine and serine derivatives, this tetrazine IEDDA decaging reaction is likely to find use for precise control of protein function in vivo.

Experimental Section

Decaging of vinyl ether duocarmycin prodrug in vitro: The N-Ac CBI prodrug 5 was diluted in PBS pH 7.4 to a final concentration of 100 μM from a 10 μM stock in acetonitrile. Then the benzoic acid tetrazine 2c was added to a final concentration of 500 μM from a 50 μM stock in DMSO. The reaction was performed at 37°C and was monitored by HPLC/UV at different times until completion.

Decaging of vinyl ether duocarmycin double prodrug 5 in cells: Cells were incubated with increasing concentrations of 5 or equivalent vehicle controls for 24 h. The culture medium was then exchanged to complete medium supplemented with increasing concentrations of tetrazine 2c, drug or equivalent vehicle controls. Cells were incubated for another 46.5 h until proceeding with the CellTiter-Blue Cell Viability Assay (Promega). Relative fluorescence units (R.U.) were normalized to the values obtained for the appropriate vehicle controls. Bars represent the average of 3 independent experiments and error bars represent standard error of the mean (SEM).

Acknowledgments

We thank the European Commission (Marie Skłodowska-Curie ITN Protein Conjugates; Marie Skłodowska-Curie IEF to E.J.M. and B.L.O.; Marie Curie IEF to O.B.), China Scholarship Council (PhD studentship to Z.G.), FCT Portugal (FCT Investigator to G.J.O.), MINECO (CTQ2015-70524-R and RYC-2013-14706 to G.J.O.), and the EPSRC for financial support. We also thank BiFi (Memento cluster) for computer support. G.J.O. is a Royal Society University Research Fellow and the recipient of a European Research Council Starting Grant (TugIt).

Conflict of interest

The authors declare no conflict of interest.
Keywords: caged compounds · ethers · heterocycles · drug delivery · fluorescent probes

How to cite: Angew. Chem. Int. Ed. 2017, 56, 243–247

Angew. Chem. 2017, 129, 249–253

[1] a) E. M. Sletten, C. R. Bertozzi, Angew. Chem. Int. Ed. 2009, 48, 6974–6984; Angew. Chem. 2009, 121, 7108–7133; b) K. Lang, J. W. Chin. Chem. Rev. 2014, 114, 4764–4806; c) N. Krall, F. P. da Cruz, O. Bouteuereira, G. J. L. Bernardes, Nat. Chem. 2016, 8, 103–113.

[2] J. Li, P. R. Chen, Nat. Chem. Biol. 2016, 12, 129–137, and references therein.

[3] D. P. Nguyen, M. Mahesh, S. J. Elsässer, S. M. Hancock, C. Urtamapinant, J. W. Chin, J. Am. Chem. Soc. 2014, 136, 2240–2243.

[4] J. Li, J. Yu, J. Zhao, J. Wang, S. Zheng, S. Lin, L. Chen, M. Yang, S. Jia, X. Zhang, P. R. Chen, Nat. Chem. 2014, 6, 352–361.

[5] J. Luo, Q. Liu, K. Moriihiro, A. Deiters, Nat. Chem. 2016, 8, 1027–1034.

[6] J. Li, S. Jia, P. R. Chen, Nat. Chem. Biol. 2014, 10, 1003–1005.

[7] J. T. Weiss, J. C. Dawson, K. G. Macleod, W. Rybski, C. Fraser, C. Torres-Sánchez, E. E. Patton, M. Bradley, N. O. Carragher, A. Unciti-Broceta, Nat. Commun. 2014, 5, 3277.

[8] R. M. Versteegen, R. Rossin, W. ten Hoeve, H. M. Janssen, M. S. Robillard, Angew. Chem. Int. Ed. 2015, 52, 14112–14116; Angew. Chem. 2015, 123, 14362–14366.

[9] a) R. Rossin, S. M. J. van Duijnholven, W. ten Hoeve, H. M. Janssen, L. H. J. Kleijn, F. J. M. Hoeben, R. M. Versteegen, M. S. Robillard, Bioconjugate Chem. 2016, 27, 1697–1706; b) G. Zhang, J. Li, R. Xie, X. Fan, Y. Liu, S. Zheng, Y. Ge, P. R. Chen, ACS Cent. Sci. 2016, 2, 325–331; c) J. M. Mejia Oneto, I. Khan, L. Seebald, M. Royzen, ACS Cent. Sci. 2016, 2, 476–482.

[10] R. Rossin, S. M. van den Bosch, W. ten Hoeve, M. Carverelli, R. M. Versteegen, J. Lab, M. S. Robillard, Bioconjugate Chem. 2013, 24, 1210–1217.

[11] a) S. Sueur, M. Lagrence, F. Abraham, C. Bremard, J. Heterocycl. Chem. 1987, 24, 1285–1289; b) D. L. Boger, S. M. Sakya, J. Org. Chem. 1988, 53, 1415–1423; c) J. Sueur, D. K. Heldmann, J. Hetzenegger, J. Krauthan, H. Siechert, J. Schuster, Eur. J. Org. Chem. 1998, 2885–2896; d) D. Che, T. Wegge, M. T. Stubbs, G. Seitz, H. Meier, C. Methfessel, J. Med. Chem. 2001, 44, 47–57; e) D. R. Soenien, J. M. Zimpleman, D. L. Boger, J. Org. Chem. 2003, 68, 3593–3598; f) A. Hamsasaki, R. Ducray, D. L. Boger, J. Org. Chem. 2006, 71, 185–193.

[12] H. Wu, S. C. Alexander, S. Jin, N. K. Devaraj, J. Am. Chem. Soc. 2016, 138, 11429–11432.

[13] a) Y. Okimoto, S. Sakaguchi, Y. Ishii, J. Am. Chem. Soc. 2002, 124, 1590–1591; b) M. Blouiu, R. Frenette, J. Org. Chem. 2001, 66, 9043–9045.

[14] a) S. T. Laughlin, C. R. Bertozzi, Proc. Natl. Acad. Sci. USA 2009, 106, 12–17; b) L. Xue, I. A. Karpenko, J. Hibli, K. Johnson, Nat. Chem. Biol. 2015, 11, 917–923.

[15] M. R. Karver, R. Weinsleider, S. A. Hilderbrand, Bioconjugate Chem. 2011, 22, 2263–2270.

[16] K. Lang, L. Davis, J. Torres-Kolbus, C. Chou, A. Deiters, J. W. Chin, Nat. Chem. 2012, 4, 298–304.

[17] I. Takahashi, K. Takahashi, M. Ichimura, M. Morimoto, K. Asano, I. Kawamoto, F. Tomita, H. Nakano, J. Antibi. 1988, 41, 1915–1917.

[18] R. C. Elgersma, R. G. E. Coumans, T. Huijbregts, W. M. P. Menge, J. A. F. Joosten, H. J. Spijker, F. M. H. de Groot, M. M. C. van der Lee, R. Ubbink, D. J. van den Dobbelsteen, D. F. Egging, W. H. A. Dokter, G. F. M. Verheijden, J. M. Lennings, C. M. Timmers, P. H. Beusker, Mol. Pharm. 2015, 12, 1813–1835.

[19] L. F. Tietze, J. M. von Hof, M. Müller, B. Krewer, I. Schuberth, Angew. Chem. Int. Ed. 2010, 49, 7336–7339; Angew. Chem. 2010, 122, 7494–7497.

[20] D. M. Tercel, S. M. Stibrbling, H. Sheppard, B. G. Siim, K. Wu, S. M. Pullen, K. J. Botting, W. R. Wilson, W. A. Denny, J. Med. Chem. 2003, 46, 2132–2151.

[21] a) P. A. Arstoiff, P. D. Johnson, D. Sun, L. H. Hurley, J. Med. Chem. 1993, 36, 1956–1963; b) M. Tercel, S. M. Stibrbling, H. Sheppard, B. G. Siim, K. Wu, S. M. Pullen, K. J. Botting, W. R. Wilson, W. A. Denny, J. Med. Chem. 2003, 46, 2132–2151.

[22] H. Bundgaard, Adv. Drug Delivery Rev. 1989, 3, 39–65.

Manuscript received: September 30, 2016
Revised: November 8, 2016
Final Article published: December 8, 2016